CORT
NASDAQCorcept Therapeutics Incorporated
News · 26 weeks92+30%
2026-03-012026-08-23
Mix4490d
- Insider29(66%)
- SEC Filings6(14%)
- Other5(11%)
- Earnings2(5%)
- Analyst2(5%)
Latest news
25 items- INSIDERDirector Mahoney David L sold $12,251,411 worth of shares (103,606 units at $118.25) as part of a pre-agreed trading plan (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDERDirector Wilson James N sold $1,114,261 worth of shares (10,000 units at $111.43) as part of a pre-agreed trading plan (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDERChief Business Officer Robb Gary Charles sold $1,162,572 worth of shares (10,000 units at $116.26) and gifted 125 shares, decreasing direct ownership by 0.92% to 13,426 units (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDEROfficer Maduck Sean exercised 3,664 shares at a strike of $8.27 and sold $419,491 worth of shares (3,664 units at $114.49) as part of a pre-agreed trading plan (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- ANALYSTTruist resumed coverage on Corcept Therapeutics with a new price targetTruist resumed coverage of Corcept Therapeutics with a rating of Buy and set a new price target of $164.00
- INSIDERChief Business Officer Robb Gary Charles gifted 11,530 shares and received a gift of 6,000 shares, decreasing direct ownership by 46% to 13,551 units (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Corcept Therapeutics IncorporatedSCHEDULE 13G/A - CORCEPT THERAPEUTICS INC (0001088856) (Subject)
- INSIDEROfficer Maduck Sean exercised 1,031 shares at a strike of $8.27 and sold $118,068 worth of shares (1,031 units at $114.52) as part of a pre-agreed trading plan (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDERChief Development Officer Guyer William exercised 16,300 shares at a strike of $21.65 and sold $1,848,890 worth of shares (16,300 units at $113.43) as part of a pre-agreed trading plan (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDERChief Development Officer Guyer William exercised 3,700 shares at a strike of $21.65 and sold $418,562 worth of shares (3,700 units at $113.12) as part of a pre-agreed trading plan (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDEROfficer Maduck Sean exercised 20,305 shares at a strike of $8.27 and sold $2,329,075 worth of shares (20,305 units at $114.70) as part of a pre-agreed trading plan (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDEROfficer Lyon Joseph Douglas sold $175,806 worth of shares (1,540 units at $114.16), decreasing direct ownership by 22% to 5,495 units (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDERChief Financial Officer Mokari Atabak sold $9,177,109 worth of shares (80,000 units at $114.71) as part of a pre-agreed trading plan and exercised 80,000 shares at a strike of $23.06 (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- SECSEC Form 10-Q filed by Corcept Therapeutics Incorporated10-Q - CORCEPT THERAPEUTICS INC (0001088856) (Filer)
- SECCorcept Therapeutics Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - CORCEPT THERAPEUTICS INC (0001088856) (Filer)
- PRCorcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate UpdateRevenue of $256.1 million, a 32 percent increase over the same period in 2025 Korlym® and authorized generic product revenue of $208.6 million Lifyorli™ product revenue of $47.6 million Increase in 2026 revenue guidance to $1.1 – $1.2 billion Net income of $43.0 million, compared to $35.1 million in second quarter 2025 Cash and investments of $544.6 million at June 30, 2026 Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quart
- ANALYSTCorcept Therapeutics downgraded by Wolfe Research with a new price targetWolfe Research downgraded Corcept Therapeutics from Peer Perform to Underperform and set a new price target of $50.00
- PRCorcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference CallCorcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report second quarter financial results and provide a corporate update on July 29, 2026. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).Conference Call InformationParticipants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number and a unique access PIN. Each access PIN will accommodate one caller.Additionally, a listen-only webcast will be available by clicking here.A replay of the call will be available on the Investors / Events tab of Corcept.com.About Corcept TherapeuticsFor over 25 y
- INSIDERDirector Wilson James N sold $882,986 worth of shares (10,000 units at $88.30) as part of a pre-agreed trading plan (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDERChief Financial Officer Mokari Atabak exercised 40,000 shares at a strike of $21.56 and sold $3,508,277 worth of shares (40,000 units at $87.71) as part of a pre-agreed trading plan (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDERChief Business Officer Robb Gary Charles gifted 600 shares, decreasing direct ownership by 2% to 25,081 units (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDERChief Development Officer Guyer William exercised 20,000 shares at a strike of $21.65 and sold $1,862,530 worth of shares (20,000 units at $93.13) as part of a pre-agreed trading plan (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDEROfficer Maduck Sean exercised 25,000 shares at a strike of $8.27 and sold $2,208,737 worth of shares (25,000 units at $88.35) as part of a pre-agreed trading plan (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDERDirector Mahoney David L sold $1,690,506 worth of shares (20,000 units at $84.53) (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDERDirector Wilson James N sold $832,049 worth of shares (10,000 units at $83.20) as part of a pre-agreed trading plan (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
CORT FAQ
7 questionsWhat does Corcept Therapeutics Incorporated do?
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in...Where does CORT stock trade?
Corcept Therapeutics Incorporated (CORT) is listed on NASDAQ.What sector and industry is CORT in?
Corcept Therapeutics Incorporated operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Corcept Therapeutics Incorporated go public?
Corcept Therapeutics Incorporated (CORT) completed its IPO in 2004.What are analysts saying about CORT?
Corcept Therapeutics Incorporated has had 8 recent analyst actions on file. The most recent action was from Truist: Buy on 2026-08-18. Recent price targets range from $3000.00 to $3800.00.What companies are similar to CORT?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare CORT side-by-side with any of them on Quantisnow.How can I track CORT on Quantisnow?
Quantisnow aggregates Corcept Therapeutics Incorporated's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CORT to receive live email and push alerts on every new disclosure.